Advertisement
AMLX vs TARA
Which Stock Would AI Choose? Amylyx Pharmaceuticals (AMLX) vs. Protara Therapeutics (TARA) Stock Comparison
Key Takeaways
- Both AMLX and TARA are clinical-stage biotechs with cash runways into 2028, but their recent stock trajectories have diverged sharply.
- AMLX rallied strongly after its lead drug candidate avexitide met its primary and all secondary endpoints in the Phase 3 LUCIDITY trial for post-bariatric hypoglycemia (PBH).
- TARA is advancing TARA-002 across non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), with several key data readouts expected in the fourth quarter of 2026.
- Recent financing patterns differ: AMLX raised roughly $500 million at an elevated share price, while TARA has relied on an at-the-market facility and holds a smaller cash position.
- AMLX trades near its multi-year highs, whereas TARA sits well below its analyst consensus price target, reflecting different risk and reward profiles.
- For more context, explore AMLX Major News and AMLX Today's Price Move, along with TARA Major News and TARA Today's Price Move.
- To see how automated systems are navigating this environment, explore Trending AI Robots.
Introduction
Investors evaluating small- and mid-cap biotechnology often compare companies with different therapeutic focuses but similar clinical-stage profiles. AMLX (Amylyx Pharmaceuticals) and TARA (Protara Therapeutics) offer a useful study in contrast: one has just delivered a pivotal late-stage data catalyst, while the other is building toward multiple near-term readouts. This stock comparison is most relevant to traders and investors who follow binary clinical events, relative momentum, and balance-sheet positioning. Understanding each company's pipeline, financing history, and market positioning can help clarify why their share prices have moved in different directions during recent weeks and what factors may drive their next leg.
AMLX Overview and Recent Performance
AMLX is a clinical-stage pharmaceutical company focused on endocrine and neurodegenerative conditions. Its lead candidate, avexitide, is a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist in development for PBH, a metabolic condition with no currently approved therapies. In recent weeks, the company reported positive topline data from the Phase 3 LUCIDITY trial, showing a 55% reduction in the composite rate of serious hypoglycemic events compared with placebo, while meeting all secondary endpoints. The news drove a substantial repricing in the stock, which had previously been pressured after the 2024 failure of its amyotrophic lateral sclerosis (ALS) drug, Relyvrio. AMLX capitalized on the rally by completing an upsized public offering that raised roughly $500 million, strengthening its balance sheet ahead of a potential 2027 launch. The company has reported an expanded pipeline including AMX0035 for Wolfram syndrome and AMX0114 for ALS, and it has indicated a cash runway into 2028.
TARA Overview and Recent Performance
TARA is a clinical-stage biotechnology company developing therapies for cancer and rare diseases. Its lead candidate, TARA-002, is an investigational cell-based therapy in development for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), while its IV Choline Chloride program targets patients on parenteral support. The company has reported encouraging interim data from its STARBORN-1 trial in pediatric LMs, with clinical success observed in the majority of evaluable patients, and it expects to submit a Biologics License Application (BLA) in the second half of 2027. Despite these clinical milestones, TARA shares have traded lower in recent months and remain well below the analyst consensus price target, which reflects a meaningful gap between current market pricing and Wall Street estimates. The company reported a cash position of approximately $161.9 million and expects funding into 2028, with multiple interim readouts, including the THRIVE-3 trial, anticipated in the fourth quarter of 2026.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading systems chosen for their suitability to current market conditions. Tickeron maintains hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only a subset earns a place in this section. These bots differ in trading style, strategy, timeframe, performance statistics, and the specific sets of tickers they follow, so no single system fits every investor. The curated list is designed to surface the robots that have demonstrated the most relevant recent performance, offering traders a way to compare quantitative approaches alongside their own fundamental research. Readers interested in how automation approaches names like AMLX and TARA can review the Trending AI Robots page to explore the available options.
Head-to-Head Comparison
The two companies differ most visibly in momentum and catalyst timing. AMLX has already realized a major positive catalyst, which lifted its valuation toward multi-year highs and enabled a large equity raise at an elevated price. The key risk now centers on execution toward regulatory submission and eventual commercialization, as well as whether the current valuation already reflects that success. TARA, by contrast, has not yet seen a comparable repricing and trades at a level that implies greater skepticism, despite holding several near-term catalysts across its oncology, rare disease, and choline programs. On sector exposure, AMLX is concentrated in metabolic and neurodegenerative disease, while TARA spans oncology and rare pediatric conditions, giving it a broader but less concentrated catalyst set. Balance-sheet strength favors AMLX in absolute terms, though both companies project runways into 2028.
Tickeron AI Verdict
Based on observable trend consistency, recent momentum, and the quality of its latest catalyst, an AI-driven framework would likely favor AMLX in the current environment. The positive Phase 3 LUCIDITY results, the successful capital raise, and the stock's ability to hold near higher levels suggest stronger relative positioning and clearer trend confirmation. TARA retains a more speculative profile, with its potential upside tied to catalysts that have not yet materialized. This assessment is probabilistic rather than definitive and reflects how a rules-based system might weigh stability and confirmed catalysts against pending binary events.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a StrongBuy and TARA is a Buy.
AMLX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for AMLX turned positive on October 20, 2026. Looking at past instances where AMLX's MACD turned positive, the stock continued to rise in 38 of 42 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMLX's RSI Indicator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on AMLX as a result. In 67 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
AMLX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMLX advanced for three days, in 233 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 189 of 218 cases where AMLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
AMLX broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AMLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.481) is normal, around the industry mean (6.379). P/E Ratio (-20.922) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
TARA's RSI Indicator recovers from oversold territory
The RSI Oscillator for TARA moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on TARA as a result. In 66 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for TARA just turned positive on October 21, 2026. Looking at past instances where TARA's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
Following a +17.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where TARA advanced for three days, in 173 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
TARA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TARA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for TARA entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.843) is normal, around the industry mean (3.498). P/E Ratio (-1.691) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. TARA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TARA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
TARA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 5 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 36 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 82 | |
P/E GROWTH RATING 1..100 | 11 | |
SEASONALITY SCORE 1..100 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AMLX | TARA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 87% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 78% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 83% | 1 day ago 87% |
| Advances ODDS (%) | 1 day ago 80% | 3 days ago 79% |
| Declines ODDS (%) | 17 days ago 81% | 7 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 77% | 1 day ago 73% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMLX’s FA Score shows that 0 FA rating(s) are green while TARA’s FA Score has 1 green FA rating(s).
- AMLX’s FA Score: 0 green, 5 red.
- TARA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMLX’s TA Score shows that 6 TA indicator(s) are bullish while TARA’s TA Score has 5 bullish TA indicator(s).
- AMLX’s TA Score: 6 bullish, 3 bearish.
- TARA’s TA Score: 5 bullish, 3 bearish.
Price Growth
AMLX (@Pharmaceuticals: Generic) experienced а +8.16% price change this week, while TARA (@Biotechnology) price change was +11.49% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.13%. For the same industry, the average monthly price growth was -6.49%, and the average quarterly price growth was +10.54%.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
AMLX is expected to report earnings on Mar 09, 2027.
TARA is expected to report earnings on Mar 10, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.13% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AMLX and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMLX has been loosely correlated with OCUL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMLX jumps, then OCUL could also see price increases.
| Ticker / NAME | Correlation To AMLX | 1D Price Change % | ||
|---|---|---|---|---|
| AMLX | 100% | +2.88% | ||
| OCUL - AMLX | 46% Loosely correlated | +0.76% | ||
| LRMR - AMLX | 45% Loosely correlated | +1.49% | ||
| JAZZ - AMLX | 43% Loosely correlated | +1.14% | ||
| RGNX - AMLX | 43% Loosely correlated | +10.14% | ||
| IDYA - AMLX | 43% Loosely correlated | +3.04% | ||
More | ||||
TARA and
Correlation & Price change
A.I.dvisor indicates that over the last year, TARA has been loosely correlated with AMLX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TARA jumps, then AMLX could also see price increases.
| Ticker / NAME | Correlation To TARA | 1D Price Change % | ||
|---|---|---|---|---|
| TARA | 100% | +7.82% | ||
| AMLX - TARA | 40% Loosely correlated | +2.88% | ||
| ARVN - TARA | 39% Loosely correlated | -0.14% | ||
| IMNM - TARA | 37% Loosely correlated | +2.25% | ||
| KURA - TARA | 37% Loosely correlated | +2.11% | ||
| ALT - TARA | 37% Loosely correlated | -0.52% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QMOM | 69.30 | 1.41 | +2.08% |
| Alpha Architect U.S. Quantitative Momentum ETF (QMOM) | |||
| NMT | 10.16 | 0.03 | +0.30% |
| Nuveen Massachusetts Quality Municipal Income Fund | |||
| TJAN | 28.82 | 0.04 | +0.13% |
| Innovator Equity Defined Protection ETF - 2 Yr to January 2027 | |||
| WDIG | 33.44 | N/A | N/A |
| WisdomTree Efficient Rare Earth Plus Strategic Metals Fund (WDIG) | |||
| EWP | 59.92 | -0.41 | -0.68% |
| iShares MSCI Spain ETF (EWP) | |||